Bloos, Frank http://orcid.org/0000-0002-0767-7941
Held, Jürgen
Schlattmann, Peter
Brillinger, Nicole
Kurzai, Oliver
Cornely, Oliver A.
Thomas-Rüddel, Daniel
Funding for this research was provided by:
Bundesministerium für Bildung und Forschung (01EO1502)
Article History
Received: 30 January 2018
Accepted: 21 August 2018
First Online: 4 September 2018
Consent for publication
: Not applicable.
: We have read and understood the TRIALS policy on declarations of interests and declare the following interests. FB, DTR, and OK belong to the institution receiving public funding for the trial. FB has received lecture honoraria from Biosyn, Gilead, and CSL Behring. JH received royalties for lectures from MSD as well as lecture royalties and a research grant from Pfizer. OAC is an unpaid member of the European Confederation of Medical Mycology and of the European Fungal Infection Study Group of the European Society for Clinical Microbiology and Infectious Diseases, which are developing joint guidelines. OAC has received research grants from Actelion, Amplyx, Arsanis, Astellas, AstraZeneca, Basilea, Bayer, Cidara, Duke University (NIH UM1AI104681), F2G, Gilead, GSK, Leeds University, Matinas, Medicines Company, MedPace, Melinta, Merck/MSD, Miltenyi, Pfizer, Rempex, Roche, Sanofi Pasteur, Scynexis, and Seres. OAC is a consultant to Amplyx, Actelion, Astellas, Basilea, Cidara, Da Volterra, F2G, Gilead, Janssen, Matinas, Menarini, Merck/MSD, Paratek, PSI, Scynexis, Seres, Summit, Tetraphase, and Vical. OAC has received lecture honoraria from Astellas, Basilea, Gilead, Merck/MSD, and Pfizer. NB and PS report no conflicts of interest.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.